SMT201500007B - Derivati di piridina bi-sostituiti come anticancro - Google Patents

Derivati di piridina bi-sostituiti come anticancro

Info

Publication number
SMT201500007B
SMT201500007B SM201500007T SM201500007T SMT201500007B SM T201500007 B SMT201500007 B SM T201500007B SM 201500007 T SM201500007 T SM 201500007T SM 201500007 T SM201500007 T SM 201500007T SM T201500007 B SMT201500007 B SM T201500007B
Authority
SM
San Marino
Prior art keywords
cancer
pyridine derivatives
substituted pyridine
substituted
derivatives
Prior art date
Application number
SM201500007T
Other languages
English (en)
Italian (it)
Inventor
Hideki Sugiyama Kazuhisa Takasu
Shigekazu Okuna Mitsuhiro Fujita
Shinya Sumida Takumi Ohtsuka
Toshiyuki Hirose
Yosuke Sato
Satoshi Yamada
Keisuke Miyajima
Koji Sakai
Yutaka Kojima
Kazuo Sekiguchi
Yasuo Yanagihara
Takashi Suzuki
Hideo Tanaka
Kazuhisa Sugiyama
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SMT201500007B publication Critical patent/SMT201500007B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SM201500007T 2010-01-29 2015-01-09 Derivati di piridina bi-sostituiti come anticancro SMT201500007B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29963110P 2010-01-29 2010-01-29
US35972910P 2010-06-29 2010-06-29
PCT/JP2011/052302 WO2011093524A1 (en) 2010-01-29 2011-01-28 Di - substituted pyridine derivatives as anticancers

Publications (1)

Publication Number Publication Date
SMT201500007B true SMT201500007B (it) 2015-03-05

Family

ID=43797869

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500007T SMT201500007B (it) 2010-01-29 2015-01-09 Derivati di piridina bi-sostituiti come anticancro

Country Status (27)

Country Link
US (1) US8722663B2 (sr)
EP (1) EP2528897B9 (sr)
JP (1) JP5335932B2 (sr)
KR (1) KR101411030B1 (sr)
CN (1) CN102791690B (sr)
AR (1) AR080057A1 (sr)
AU (1) AU2011211306B2 (sr)
CA (1) CA2788073A1 (sr)
CO (1) CO6561817A2 (sr)
DK (1) DK2528897T3 (sr)
EA (1) EA026042B1 (sr)
ES (1) ES2521016T3 (sr)
HR (1) HRP20141190T1 (sr)
IL (1) IL221146A (sr)
MX (1) MX2012008391A (sr)
MY (1) MY160875A (sr)
NZ (1) NZ601794A (sr)
PH (1) PH12012501532A1 (sr)
PL (1) PL2528897T3 (sr)
PT (1) PT2528897E (sr)
RS (1) RS53705B1 (sr)
SG (1) SG182663A1 (sr)
SI (1) SI2528897T1 (sr)
SM (1) SMT201500007B (sr)
TW (1) TWI404713B (sr)
UA (1) UA107692C2 (sr)
WO (1) WO2011093524A1 (sr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013047223A (ja) * 2011-07-28 2013-03-07 Otsuka Pharmaceut Co Ltd 医薬
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
WO2015027067A2 (en) * 2013-08-23 2015-02-26 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) * 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Kras g12c変異体タンパク質のインヒビター
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
KR20210003780A (ko) 2018-04-05 2021-01-12 스미토모 다이니폰 파마 온콜로지, 인크. Axl 키나제 억제제 및 그의 용도
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CN112812781B (zh) * 2021-01-21 2023-09-29 西安瑞联新材料股份有限公司 一种基于双哌嗪类苯并噁唑液晶化合物及其制备方法
CN116903587B (zh) * 2023-06-01 2024-03-22 三峡大学 一种角鲨烯环氧酶抑制剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301880A (ja) * 1985-09-03 1988-12-08 Otsuka Pharmaceut Co Ltd 5−フルオロウラシル誘導体
AR015733A1 (es) * 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
US6262088B1 (en) * 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
JP2001089450A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ピリジン誘導体含有医薬製剤
JP2001089412A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
JP2002226429A (ja) * 2001-02-06 2002-08-14 Fuji Photo Film Co Ltd アクリル酸エステル化合物の製造方法
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
ZA200700811B (en) * 2004-08-06 2008-10-29 Otsuka Pharma Co Ltd Aromatic compound
CN101321529B (zh) * 2005-12-05 2012-09-05 大塚制药株式会社 作为抗肿瘤剂的二芳基醚衍生物
JP5142513B2 (ja) * 2005-12-05 2013-02-13 大塚製薬株式会社 医薬
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
US20100136509A1 (en) 2007-07-02 2010-06-03 Alden Mejer System and method for clinical trial investigator meeting delivery and training including dynamic media enrichment
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物
DE202009007345U1 (de) 2009-05-22 2009-09-10 Schebo (R) . Biotech Ag Neue Pharmazeutika und Arzneimittelzubereitungen

Also Published As

Publication number Publication date
IL221146A (en) 2015-11-30
EP2528897A1 (en) 2012-12-05
WO2011093524A9 (en) 2011-12-01
ES2521016T3 (es) 2014-11-12
WO2011093524A1 (en) 2011-08-04
US20120283242A1 (en) 2012-11-08
PH12012501532A1 (en) 2012-10-22
CO6561817A2 (es) 2012-11-15
KR101411030B1 (ko) 2014-06-30
KR20120065268A (ko) 2012-06-20
CN102791690B (zh) 2015-12-02
HK1178523A1 (en) 2013-09-13
EA026042B1 (ru) 2017-02-28
MY160875A (en) 2017-03-31
EP2528897B1 (en) 2014-10-15
EP2528897B9 (en) 2015-04-22
EA201290720A1 (ru) 2013-02-28
RS53705B1 (sr) 2015-04-30
UA107692C2 (uk) 2015-02-10
AU2011211306B2 (en) 2016-07-07
US8722663B2 (en) 2014-05-13
HRP20141190T1 (hr) 2015-01-30
AR080057A1 (es) 2012-03-07
DK2528897T3 (en) 2014-12-08
JP5335932B2 (ja) 2013-11-06
AU2011211306A1 (en) 2012-08-16
TWI404713B (zh) 2013-08-11
MX2012008391A (es) 2012-08-15
PT2528897E (pt) 2014-11-12
JP2012525324A (ja) 2012-10-22
PL2528897T3 (pl) 2015-03-31
NZ601794A (en) 2014-04-30
SG182663A1 (en) 2012-08-30
CA2788073A1 (en) 2011-08-04
CN102791690A (zh) 2012-11-21
SI2528897T1 (sl) 2015-02-27
TW201136912A (en) 2011-11-01

Similar Documents

Publication Publication Date Title
SMT201500007B (it) Derivati di piridina bi-sostituiti come anticancro
CY2022027I1 (el) Παραγωγα βενζιμιδαζολο-προλινης
LTC2620436I2 (lt) Pakeistojo policiklinio karbamoilpiridono darinio provaistas
SMT201600298B (it) Derivati n3-sostituiti-n1-solfonil-5- fluoropirimidinone
SMT201600205B (it) DERIVATI BENZOTIOFENICI SOSTITUITI CON PIPERAZINA COME AGENTI ANTlPSICOTICI
SMT201600198B (it) Derivati di 1,2,4-triazina-4-ammina
SMT201500270B (it) Derivati di pirrolotriazinone come inibitori di pi3k
HRP20181884T1 (hr) Derivati piridina i pirazina
SMT201900679T1 (it) Derivati deuterati di ivacaftor
ME03469B (me) DERIVATI C4-MONOMETIL TRITERPENOIDA l POSTUPCI ZA NJIHOVU UPOTREBU
HUE037736T2 (hu) Piridin származékok
HRP20170196T1 (hr) Derivati dušikovih iperita
HRP20180672T1 (hr) Novi derivati piridina
HUE038714T2 (hu) Dispiropirrolidin származék
CO7071126A2 (es) Derivados de piridona
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
LT2791160T (lt) Modifikuotos mrnr sudėtys
PL2672840T3 (pl) Kompozycja stewii
DK2590974T3 (da) Tetrahydropyridopyrimidinderivater
SMT201600076B (it) Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo
DK2343051T3 (da) Anti-cancer formulering
SMT201400080B (it) Derivati di pirazinoossazepina
SMT201600405B (it) Derivati di arilalchilamminocarbossammide fluorurati
CO6960557A2 (es) Derivados de 2-yodo-imidazol
SMT201500113B (it) Processp per preparare derivati di alfa-carbossammide